

# DANNY NGUYEN, M.D.

---

## **Business Address**

Pacific Shores Medical Group  
1043 Elm Avenue, Suite 104  
Long Beach, CA 90813  
Phone: 562-590-0345  
Fax: 562-437-8139

## **Additional Offices Addresses**

Pacific Shores Medical Group  
19582 Beach Blvd., Suite 212  
Huntington Beach, CA 92648  
Phone: 714-252-9415  
Fax: 714-963-8407

Pacific Shores Medical Group  
16300 Sand Canyon Avenue, #207  
Irvine, CA 92618  
Phone: 949-333-7580  
Fax: 949-333-7599

Email: [dannyn@pacshoresoncology.com](mailto:dannyn@pacshoresoncology.com)

## **Current Practice Affiliation**

July 2016- Present                      Pacific Shores Medical Group

## **Education & Training**

July 2013-June 2016                      Fellowship, Hematology-Oncology  
University of South Florida, H Lee Moffitt Cancer Center

July 2010-June 2013                      Internship and Residency, Internal Medicine  
Emory School of Medicine, Atlanta, Georgia

June 2006-May 2010                      **MD** University of South Florida, Tampa, Florida

July 2002-May 2006                      **BS** Molecular and Microbiology  
University of Central Florida, Orlando, Florida

## **Licensures**

Medical board of California (A140186)

## **Specialty Boards**

# DANNY NGUYEN, M.D.

2013-American Board of Internal Medicine

2016-American Board of Medical Oncology and Hematology

## **Society Memberships**

Member, American Medical Association

Member, American Society of Clinical Oncology

Member, American Society of Hematology

## **Honors and Awards**

2015 Winner, Moffitt Symposium, in collaboration with Jason Brayer for: A novel role for histone deacetylase 11 (HDAC 11) B cell lymphopoiesis and plasma cell survival in multiple myeloma.

## **Hospital Affiliations**

Hoag Memorial Hospital (Newport Beach, Irvine), Orange Coast Memorial Medical Center, Saddleback Memorial Medical Center, Long Beach Memorial Medical Center, Los Alamitos Medical Center, St. Mary Medical Center

## **Teaching Experience**

Emory University School of Medicine, Internal Medicine Morning Report, Grand Rounds

University of South Florida College of Medicine, formal teaching conferences

## **Research Experience**

- The regulation of IL-10 by HDAC 11.
- Breast cancer characteristics in patients on anti-hormonal therapy.
- The regulation of myeloma plasma cell survival via HDAC 11.

## **Publications**

1. Alejandro Villagra, Hong-Wei Wang, Danny Nguyen, Eduardo M Sotomayor, et al. The histone deacetylase HDAC 11 regulates the expression interleukin 10 and immune tolerance. *Nature Immunology*. Vol.10, No. 1, January 2009. Page 92-100.
2. Amit Mahipal, Danny Nguyen. Risk and Benefits of Phase I Clinical Trial Participation. *Cancer Control*. Vol. 21, No. 3, July 2014. Page 193-199.

## **Abstracts**

1. Heloisa P. Soares, Danny Nguyen, Gregory M. Springet, Richard D. Kim, Irene Williams-Elson, Kara Miller, Nishi Kothari, Amit Mahipal. A phase I trial with cohort expansion of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer. *J Clin Oncol* 34, 2016 (suppl 4S; abstr TPS-467).

## **Book Chapters**

## DANNY NGUYEN, M.D.

1. Tchekmedyian N, **Nguyen D**, Bello C. (2016, in press). Marginal Zone Lymphoma. In Sallman DA, Chaudhury A, Nguyen J, Zhang L, List AF (Ed.), *Handbook of Hematologic Malignancies*. New York, New York: Demos Medical.
2. **Nguyen D**, Tchekmedyian N, Abramson, J. (2016, in press). HIV-Related Lymphomas. In Sallman DA, Chaudhury A, Nguyen J, Zhang L, List AF (Ed.), *Handbook of Hematologic Malignancies*. New York, New York: Demos Medical.

### Clinical Research Experience

*A Phase I Trial With Cohort Expansion of XXXXX in Combination With XXXXXXXXXXXX and (XXX)-XXXXXXXXXX in Locally Advanced and Metastatic Pancreatic Cancer*

**FROM:** <https://clinicaltrials.gov/ct2/show/NCT02155088> (IDENTIFICATION NUMBER **NCT02155088**)

*COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of XXXXXXXXXXXX (XXXXXX) in Combination With XXXXXXXXXXXX for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease*

**FROM:** <https://clinicaltrials.gov/ct2/show/NCT02941926> (IDENTIFICATION NUMBER **NCT02941926**)

*A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of XXXX/X Therapy/XXXXXXXXXXXXXXXXXX*

**FROM:** <https://clinicaltrials.gov/ct2/show/NCT03050398> (IDENTIFICATION NUMBER **NCT03050398**)

*A Phase II, Multicenter Study of Oral XXXX Inhibitor XXXXXX in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC)*

**FROM:** <https://clinicaltrials.gov/ct2/show/NCT02414139> (IDENTIFICATION NUMBER **NCT02414139**)

*Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of XXXXXXXXXXXX Combined with XXXXXXXXXXXXX in Participants With Advanced or Metastatic Solid Tumors*

**FROM:** <https://clinicaltrials.gov/ct2/show/NCT03098550> (IDENTIFICATION NUMBER **NCT03098550**)

*Phase 3b/4 Safety Trial of XXXXXXXXXXXX Combined With XXXXXXXXXXXX in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivolumAb Clinical Trial Evaluation 920)*

**FROM:** <https://clinicaltrials.gov/ct2/show/NCT02982954> (IDENTIFICATION NUMBER **NCT02982954**)

*Randomized, Open-label, Phase 3 Trial of XXXXXXXXXXXX Plus XXXXXXXXXXXX XXXXXXXX Versus XXXXXXXXXXXX XXXXXXXX Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate: CHECKpoint Pathway and nivolumAb Clinical Trial Evaluation 812)*

**FROM:** <https://clinicaltrials.gov/ct2/show/NCT03138499> (IDENTIFICATION NUMBER **NCT03138499**)